Nctid:
NCT00002529
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D001943", "term"=>"Breast Neoplasms"}], "ancestors"=>[{"id"=>"D009371", "term"=>"Neoplasms by Site"}, {"id"=>"D009369", "term"=>"Neoplasms"}, {"id"=>"D001941", "term"=>"Breast Diseases"}, {"id"=>"D012871", "term"=>"Skin Diseases"}], "browseLeaves"=>[{"id"=>"M5220", "name"=>"Breast Neoplasms", "asFound"=>"Breast Cancer", "relevance"=>"HIGH"}, {"id"=>"M5218", "name"=>"Breast Diseases", "relevance"=>"LOW"}, {"id"=>"M15674", "name"=>"Skin Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Neoplasms", "abbrev"=>"BC04"}, {"name"=>"Skin and Connective Tissue Diseases", "abbrev"=>"BC17"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D013629", "term"=>"Tamoxifen"}, {"id"=>"D017312", "term"=>"Toremifene"}, {"id"=>"D003520", "term"=>"Cyclophosphamide"}, {"id"=>"D004317", "term"=>"Doxorubicin"}, {"id"=>"C506643", "term"=>"Liposomal doxorubicin"}, {"id"=>"D015251", "term"=>"Epirubicin"}], "ancestors"=>[{"id"=>"D007166", "term"=>"Immunosuppressive Agents"}, {"id"=>"D007155", "term"=>"Immunologic Factors"}, {"id"=>"D045505", "term"=>"Physiological Effects of Drugs"}, {"id"=>"D018501", "term"=>"Antirheumatic Agents"}, {"id"=>"D018906", "term"=>"Antineoplastic Agents, Alkylating"}, {"id"=>"D000477", "term"=>"Alkylating Agents"}, {"id"=>"D045504", "term"=>"Molecular Mechanisms of Pharmacological Action"}, {"id"=>"D000970", "term"=>"Antineoplastic Agents"}, {"id"=>"D019653", "term"=>"Myeloablative Agonists"}, {"id"=>"D000903", "term"=>"Antibiotics, Antineoplastic"}, {"id"=>"D059005", "term"=>"Topoisomerase II Inhibitors"}, {"id"=>"D059003", "term"=>"Topoisomerase Inhibitors"}, {"id"=>"D004791", "term"=>"Enzyme Inhibitors"}, {"id"=>"D004965", "term"=>"Estrogen Antagonists"}, {"id"=>"D006727", "term"=>"Hormone Antagonists"}, {"id"=>"D006730", "term"=>"Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id"=>"D018931", "term"=>"Antineoplastic Agents, Hormonal"}, {"id"=>"D020845", "term"=>"Selective Estrogen Receptor Modulators"}, {"id"=>"D020847", "term"=>"Estrogen Receptor Modulators"}, {"id"=>"D050071", "term"=>"Bone Density Conservation Agents"}], "browseLeaves"=>[{"id"=>"M7492", "name"=>"Doxorubicin", "asFound"=>"Intravenous infusion", "relevance"=>"HIGH"}, {"id"=>"M227339", "name"=>"Liposomal doxorubicin", "asFound"=>"Intravenous infusion", "relevance"=>"HIGH"}, {"id"=>"M6727", "name"=>"Cyclophosphamide", "asFound"=>"Was", "relevance"=>"HIGH"}, {"id"=>"M9789", "name"=>"Hormones", "relevance"=>"LOW"}, {"id"=>"M17954", "name"=>"Epirubicin", "asFound"=>"Nebulization", "relevance"=>"HIGH"}, {"id"=>"M16403", "name"=>"Tamoxifen", "asFound"=>"Thrombocytopenia", "relevance"=>"HIGH"}, {"id"=>"M21320", "name"=>"Citric Acid", "relevance"=>"LOW"}, {"id"=>"M1837", "name"=>"Sodium Citrate", "relevance"=>"LOW"}, {"id"=>"M19601", "name"=>"Toremifene", "asFound"=>"Glenoid", "relevance"=>"HIGH"}, {"id"=>"M10212", "name"=>"Immunosuppressive Agents", "relevance"=>"LOW"}, {"id"=>"M10201", "name"=>"Immunologic Factors", "relevance"=>"LOW"}, {"id"=>"M20604", "name"=>"Antirheumatic Agents", "relevance"=>"LOW"}, {"id"=>"M20942", "name"=>"Antineoplastic Agents, Alkylating", "relevance"=>"LOW"}, {"id"=>"M3820", "name"=>"Alkylating Agents", "relevance"=>"LOW"}, {"id"=>"M4222", "name"=>"Anti-Bacterial Agents", "relevance"=>"LOW"}, {"id"=>"M4224", "name"=>"Antibiotics, Antitubercular", "relevance"=>"LOW"}, {"id"=>"M7951", "name"=>"Enzyme Inhibitors", "relevance"=>"LOW"}, {"id"=>"M8116", "name"=>"Estrogens", "relevance"=>"LOW"}, {"id"=>"M8114", "name"=>"Estrogen Antagonists", "relevance"=>"LOW"}, {"id"=>"M30483", "name"=>"Estrogen Receptor Antagonists", "relevance"=>"LOW"}, {"id"=>"M9788", "name"=>"Hormone Antagonists", "relevance"=>"LOW"}, {"id"=>"M20966", "name"=>"Antineoplastic Agents, Hormonal", "relevance"=>"LOW"}, {"id"=>"M22599", "name"=>"Estrogen Receptor Modulators", "relevance"=>"LOW"}, {"id"=>"M22597", "name"=>"Selective Estrogen Receptor Modulators", "relevance"=>"LOW"}, {"id"=>"T382", "name"=>"Citrate", "asFound"=>"And/or", "relevance"=>"HIGH"}], "browseBranches"=>[{"name"=>"Antineoplastic Agents", "abbrev"=>"ANeo"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Antirheumatic Agents", "abbrev"=>"ARhu"}, {"name"=>"Bone Density Conservation Agents", "abbrev"=>"BDCA"}, {"name"=>"Anticoagulants", "abbrev"=>"AnCoag"}, {"name"=>"Anti-Infective Agents", "abbrev"=>"Infe"}, {"name"=>"Other Dietary Supplements", "abbrev"=>"Ot"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE3"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL"}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>452}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1993-05"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2012-07", "completionDateStruct"=>{"date"=>"2010-08", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2013-04-03", "studyFirstSubmitDate"=>"1999-11-01", "studyFirstSubmitQcDate"=>"2004-07-28", "lastUpdatePostDateStruct"=>{"date"=>"2013-04-04", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"2004-07-29", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"2010-08", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Overall survival", "timeFrame"=>"17 years after randomization", "description"=>"Time from randomization to death."}], "secondaryOutcomes"=>[{"measure"=>"Disease-free and systemic disease-free survival.", "timeFrame"=>"17 years from randomization", "description"=>"Time from randomization to recurrence, metastasis, appearance of a second primary tumor or death."}, {"measure"=>"Quality of life", "timeFrame"=>"17 years from randomization", "description"=>"Quality of life will be assessed using QL Questionnaires of IBCSG."}, {"measure"=>"Toxicity", "timeFrame"=>"17 years after randomization", "description"=>"Assessment of toxicity according to standard criteria."}]}, "oversightModule"=>{"oversightHasDmc"=>true}, "conditionsModule"=>{"keywords"=>["stage II breast cancer", "stage IIIA breast cancer"], "conditions"=>["Breast Cancer"]}, "referencesModule"=>{"references"=>[{"pmid"=>"19062268", "type"=>"BACKGROUND", "citation"=>"Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer. 2009 Mar;45(4):561-71. doi: 10.1016/j.ejca.2008.10.011. Epub 2008 Dec 4."}, {"pmid"=>"19596212", "type"=>"BACKGROUND", "citation"=>"Kenne Sarenmalm E, Oden A, Ohlen J, Gaston-Johansson F, Holmberg SB. Changes in health-related quality of life may predict recurrent breast cancer. Eur J Oncol Nurs. 2009 Dec;13(5):323-9. doi: 10.1016/j.ejon.2009.05.002. Epub 2009 Jul 12."}, {"pmid"=>"18953651", "type"=>"BACKGROUND", "citation"=>"Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thurlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25."}, {"pmid"=>"18458044", "type"=>"BACKGROUND", "citation"=>"Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5."}, {"pmid"=>"17237474", "type"=>"BACKGROUND", "citation"=>"Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thurlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007 Apr;18(4):701-8. doi: 10.1093/annonc/mdl492. Epub 2007 Jan 20."}, {"pmid"=>"16369994", "type"=>"BACKGROUND", "citation"=>"Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A; International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006 Feb 1;106(3):505-13. doi: 10.1002/cncr.21651."}, {"pmid"=>"15550579", "type"=>"BACKGROUND", "citation"=>"International Breast Cancer Study Group; Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004 Dec;15(12):1749-59. doi: 10.1093/annonc/mdh463."}]}, "descriptionModule"=>{"briefSummary"=>"RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer.\n\nPURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer.", "detailedDescription"=>"OBJECTIVES: I. Compare overall survival and local and systemic disease-free survival produced by adjuvant chemoendocrine therapy with 4 courses of anthracycline/cyclophosphamide and concurrent vs. sequential tamoxifen (TMX) or toremifene (TOR) in peri- and postmenopausal women with node-positive breast cancer who are considered suitable for endocrine therapy alone. II. Evaluate these same endpoints in patients randomized to chemoendocrine therapy vs. endocrine therapy alone. III. Evaluate these same endpoints in patients randomized to TMX vs. TOR as the endocrine therapy agent. IV. Compare the quality of life of patients treated on these regimens. V. Compare the toxic effects of these regimens.\n\nOUTLINE: This is a randomized study. Patients are stratified by type of primary therapy and participating institution. Therapy must begin within 6 weeks of surgery. Patients in the first group receive doxorubicin (or epirubicin) and cyclophosphamide every 28 days for a total of 4 cycles and oral tamoxifen daily for 5 years, beginning day 1 of chemotherapy. Patients in the second group receive the same chemotherapy with oral tamoxifen initiated on day 8 of the fourth chemotherapy cycle and continued for 5 years. Patients in the third group receive oral tamoxifen daily for 5 years. Patients in the fourth group are treated the same as the first group, only tamoxifen is replaced by toremifene. Patients in the fifth group are treated the same as the second group, only tamoxifen is replaced by toremifene. Patients in the sixth group receive oral toremifene daily for 5 years. The timing of optional radiotherapy for patients with less than total mastectomy in each group is based on institutional policy; radiotherapy is administered for 5-6 weeks to the remaining breast tissue, chest wall, and lung. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and yearly thereafter.\n\nPROJECTED ACCRUAL: 1,140 patients will be accrued over approximately 9 years, with 1 additional year of follow-up."}, "eligibilityModule"=>{"sex"=>"FEMALE", "stdAges"=>["CHILD", "ADULT", "OLDER_ADULT"], "maximumAge"=>"70 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"DISEASE CHARACTERISTICS: Histologically proven stage T1-3, pN1, M0 carcinoma of the breast considered suitable for adjuvant treatment with endocrine therapy alone Estrogen receptor at least 10 fmol/mg cytosol protein or positive on immunohistochemical assay Potentially curative resection within 6 weeks of entry by one of the following: Total mastectomy with negative margins Breast-conserving procedure (lumpectomy or quadrantectomy) for tumors less than 5 cm Adequate re-resection or mastectomy within 4 weeks of initial surgery required if margins are positive after initial surgery Axillary clearance (not sampling) required at surgery, with at least 1 node positive upon histopathologic examination of at least 8 nodes Suspicious manifestations of metastatic disease (e.g., hot spots on bone scan, skeletal pain of unknown cause) must be proven benign No bilateral breast cancer Any mass in contralateral breast must be proven benign by biopsy\n\nPATIENT CHARACTERISTICS: Age: 70 and under Sex: Women only Menopausal status: Peri/postmenopausal, i.e.: More than 6 months since last normal menstrual period (LNMP) with no prior hysterectomy and no hormone replacement therapy (HRT) Prior hysterectomy and no HRT and either age greater than 55 or age 55 or less with postmenopausal LH, FSH, and E2 levels On HRT and either age 50 or greater or LNMP more than 6 months prior to starting HRT Performance status: Not specified Hematopoietic: WBC greater than 4,000 Platelets greater than 100,000 Hepatic: Bilirubin less than 1.1 mg/dL (20 micromoles/L) AST less than 60 IU/L Renal: Creatinine less than 1.3 mg/dL (120 micromoles/L) Other: No nonmalignant systemic disease that would preclude protocol therapy or prolonged follow-up No psychiatric or addictive disorder that would preclude informed consent No prior or concurrent second malignancy except: Nonmelanomatous skin cancer Adequately treated in situ carcinoma of the cervix Geographically accessible for follow-up\n\nPRIOR CONCURRENT THERAPY: No prior therapy for breast cancer other than potentially curative surgery (see Disease Characteristics)"}, "identificationModule"=>{"nctId"=>"NCT00002529", "acronym"=>"12-93", "briefTitle"=>"Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer", "organization"=>{"class"=>"NETWORK", "fullName"=>"ETOP IBCSG Partners Foundation"}, "officialTitle"=>"Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.", "orgStudyIdInfo"=>{"id"=>"CDR0000078385"}, "secondaryIdInfos"=>[{"id"=>"IBCSG-12-93", "type"=>"OTHER", "domain"=>"International Breast Cancer Study Group"}, {"id"=>"EU-93015"}, {"id"=>"NCI-F93-0010"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"AC with concurrent tamoxifen", "description"=>"AC for 4 cycles with concurrent tamoxifen for 5 years", "interventionNames"=>["Drug: cyclophosphamide", "Drug: doxorubicin hydrochloride", "Drug: epirubicin hydrochloride", "Drug: tamoxifen citrate"]}, {"type"=>"EXPERIMENTAL", "label"=>"AC followed by tamoxifen", "description"=>"AC for 4 cycles followed by tamoxifen to 5 years from randomization.", "interventionNames"=>["Drug: cyclophosphamide", "Drug: doxorubicin hydrochloride", "Drug: epirubicin hydrochloride", "Drug: tamoxifen citrate"]}, {"type"=>"EXPERIMENTAL", "label"=>"Tamoxifen alone", "description"=>"Tamoxifen alone for 5 years.", "interventionNames"=>["Drug: tamoxifen citrate"]}, {"type"=>"EXPERIMENTAL", "label"=>"AC with concurrent toremifene", "description"=>"AC for 4 cycles with concurrent toremifene for 5 years.", "interventionNames"=>["Drug: cyclophosphamide", "Drug: doxorubicin hydrochloride", "Drug: epirubicin hydrochloride", "Drug: toremifene"]}, {"type"=>"EXPERIMENTAL", "label"=>"AC followed by toremifene", "description"=>"AC for 4 cycles followed by toremifene to 5 years from randomization.", "interventionNames"=>["Drug: cyclophosphamide", "Drug: doxorubicin hydrochloride", "Drug: epirubicin hydrochloride", "Drug: toremifene"]}, {"type"=>"EXPERIMENTAL", "label"=>"Toremifene alone", "description"=>"Toremifene alone for 5 years.", "interventionNames"=>["Drug: toremifene"]}], "interventions"=>[{"name"=>"cyclophosphamide", "type"=>"DRUG", "description"=>"cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days", "armGroupLabels"=>["AC followed by tamoxifen", "AC followed by toremifene", "AC with concurrent tamoxifen", "AC with concurrent toremifene"]}, {"name"=>"doxorubicin hydrochloride", "type"=>"DRUG", "description"=>"doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.", "armGroupLabels"=>["AC followed by tamoxifen", "AC followed by toremifene", "AC with concurrent tamoxifen", "AC with concurrent toremifene"]}, {"name"=>"epirubicin hydrochloride", "type"=>"DRUG", "description"=>"epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.", "armGroupLabels"=>["AC followed by tamoxifen", "AC followed by toremifene", "AC with concurrent tamoxifen", "AC with concurrent toremifene"]}, {"name"=>"tamoxifen citrate", "type"=>"DRUG", "description"=>"Tamoxifen 20 mg daily.", "armGroupLabels"=>["AC followed by tamoxifen", "AC with concurrent tamoxifen", "Tamoxifen alone"]}, {"name"=>"toremifene", "type"=>"DRUG", "description"=>"Toremifene 60 mg daily.", "armGroupLabels"=>["AC followed by toremifene", "AC with concurrent toremifene", "Toremifene alone"]}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"NSW 2310", "city"=>"Newcastle", "state"=>"New South Wales", "country"=>"Australia", "facility"=>"Newcastle Mater Misericordiae Hospital", "geoPoint"=>{"lat"=>-32.92715, "lon"=>151.77647}}, {"zip"=>"2050", "city"=>"Sydney", "state"=>"New South Wales", "country"=>"Australia", "facility"=>"Royal Prince Alfred Hospital, Sydney", "geoPoint"=>{"lat"=>-33.86785, "lon"=>151.20732}}, {"zip"=>"5000", "city"=>"Adelaide", "state"=>"South Australia", "country"=>"Australia", "facility"=>"Royal Adelaide Hospital", "geoPoint"=>{"lat"=>-34.92866, "lon"=>138.59863}}, {"zip"=>"3053", "city"=>"Carlton South", "state"=>"Victoria", "country"=>"Australia", "facility"=>"Anti-Cancer Council of Victoria, Melbourne"}, {"zip"=>"6009", "city"=>"Perth", "state"=>"Western Australia", "country"=>"Australia", "facility"=>"Sir Charles Gairdner Hospital, Perth", "geoPoint"=>{"lat"=>-31.95224, "lon"=>115.8614}}, {"zip"=>"33081", "city"=>"Aviano", "country"=>"Italy", "facility"=>"Centro di Riferimento Oncologico - Aviano", "geoPoint"=>{"lat"=>46.07056, "lon"=>12.59472}}, {"zip"=>"25124", "city"=>"Brescia", "country"=>"Italy", "facility"=>"Universita di Brescia", "geoPoint"=>{"lat"=>45.53558, "lon"=>10.21472}}, {"zip"=>"20141", "city"=>"Milano", "country"=>"Italy", "facility"=>"Istituto Europeo Di Oncologia", "geoPoint"=>{"lat"=>45.46427, "lon"=>9.18951}}, {"zip"=>"47037", "city"=>"Rimini", "country"=>"Italy", "facility"=>"Ospedale Civile Rimini", "geoPoint"=>{"lat"=>44.05755, "lon"=>12.56528}}, {"zip"=>"00144", "city"=>"Rome", "country"=>"Italy", "facility"=>"Ospedale San Eugenio", "geoPoint"=>{"lat"=>41.89193, "lon"=>12.51133}}, {"zip"=>"5", "city"=>"Auckland", "country"=>"New Zealand", "facility"=>"Auckland Adventist Hospital", "geoPoint"=>{"lat"=>-36.84853, "lon"=>174.76349}}, {"zip"=>"Sl-1000", "city"=>"Ljubljana", "country"=>"Slovenia", "facility"=>"Institute of Oncology, Ljubljana", "geoPoint"=>{"lat"=>46.05108, "lon"=>14.50513}}, {"zip"=>"7925", "city"=>"Cape Town", "country"=>"South Africa", "facility"=>"Groote Schuur Hospital, Cape Town", "geoPoint"=>{"lat"=>-33.92584, "lon"=>18.42322}}, {"zip"=>"S-413 45", "city"=>"Gothenburg (Goteborg)", "country"=>"Sweden", "facility"=>"Sahlgrenska University Hospital", "geoPoint"=>{"lat"=>57.70716, "lon"=>11.96679}}, {"zip"=>"CH-4031", "city"=>"Basel", "country"=>"Switzerland", "facility"=>"University Hospital", "geoPoint"=>{"lat"=>47.55839, "lon"=>7.57327}}, {"zip"=>"CH-3010", "city"=>"Bern", "country"=>"Switzerland", "facility"=>"Inselspital, Bern", "geoPoint"=>{"lat"=>46.94809, "lon"=>7.44744}}, {"zip"=>"CH-1011", "city"=>"Lausanne", "country"=>"Switzerland", "facility"=>"Centre Hospitalier Universitaire Vaudois", "geoPoint"=>{"lat"=>46.516, "lon"=>6.63282}}, {"zip"=>"2000", "city"=>"Neuchatel", "country"=>"Switzerland", "facility"=>"Hopital des Cadolles, Neuchatel", "geoPoint"=>{"lat"=>46.99179, "lon"=>6.931}}, {"zip"=>"CH-9007", "city"=>"Saint Gallen", "country"=>"Switzerland", "facility"=>"Kantonsspital - Saint Gallen", "geoPoint"=>{"lat"=>47.42391, "lon"=>9.37477}}, {"zip"=>"CH-8091", "city"=>"Zurich", "country"=>"Switzerland", "facility"=>"Universitaetsspital", "geoPoint"=>{"lat"=>47.36667, "lon"=>8.54999}}], "overallOfficials"=>[{"name"=>"Edda Simoncini, MD", "role"=>"STUDY_CHAIR", "affiliation"=>"Spedali Civili di Brescia"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"ETOP IBCSG Partners Foundation", "class"=>"NETWORK"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
